Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer - Episode 8

The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer

December 18, 2023

Floortje J. Backes, MD, Matthew A. Powell, MD, Washington University in St. Louis

Floor Backes, MD, and Matthew Powell, MD, review data on sacituzumab govitecan, an antibody-drug conjugate targeting topoisomerase in patients with advanced endometrial cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Recent Advances in Endometrial Cancer

EP. 2: Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting

EP. 3: Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer

EP. 4: Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial

EP. 5: Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer

EP. 6: The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer

EP. 7: Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer

Now Viewing

EP. 8: The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer

EP. 9: Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

EP. 10: Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer